Laser therapy for genitourinary syndrome of menopause: systematic review and meta-analysis of randomized controlled trial.

Autor:	Pessoa LLMN; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., de Souza ATB; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., Sarmento ACA; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., Ferreira Costa AP; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., Kelly Dos Santos I; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., Pereira de Azevedo E; Universidade Potiguar NatalRN Brazil Universidade Potiguar, Natal, RN, Brazil., de Medeiros KS; Liga Norteriograndense contra o Câncer NatalRN Brazil Liga Norteriograndense contra o Câncer, Natal, RN, Brazil., Gonçalves AK; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., Cobucci RN; Universidade Federal do Rio Grande do Norte NatalRN Brazil Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.; Universidade Potiguar NatalRN Brazil Universidade Potiguar, Natal, RN, Brazil.
Jazyk:	angličtina
Zdroj:	Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia [Rev Bras Ginecol Obstet] 2024 May 27; Vol. 46. Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).
DOI:	10.61622/rbgo/2024rbgo38
Abstrakt:	Objective: This meta-analysis of randomized controlled trials (RCTs) aimed to update evidence on the effectiveness and safety of laser therapy for treating genitourinary syndrome of menopause (GSM). Data Sources: Manuscripts published until May 2023 were systematically searched in PubMed; Embase; Scopus; Web of Science; CENTRAL; CINAHL; and clinical trial databases (www.trialscentral.org, www.controlled-trials.com, and clinicaltrials.gov), with no language and year of publication restriction. Studies Selection: RCTs with women diagnosed with GSM, and the intervention was vaginal laser therapy (CO2-laser or Er: YAG-laser) comparing with placebo (sham therapy), no treatment or vaginal estrogen therapy. Data Collection: Two authors evaluated the publications for inclusion based on the title and abstract, followed by reviewing the relevant full-text articles. Disagreements during the review process were addressed by consensus, with the involvement of a third author. Data Synthesis: Twelve RCTs, representing a total of 5147 participants, were included in this review. Vaginal health index (VHI) significantly improved in the carbon dioxide laser (CO2-laser) therapy group (MD=2.21; 95% CI=1.25 to 3.16), while dyspareunia (MD=-0.85; 95% CI=-1.59 to -0.10), dryness (MD=-0.62; 95% CI=-1.12 to -0.12) and burning (MD= -0.64; 95% CI=-1.28 to -0.01) decreased. No serious adverse effects were reported. Conclusion: CO2-laser increases VHI score and decreases dyspareunia, dryness and burning, especially when compared to sham-laser. However, the certainty of the evidence is low, thus preventing the recommendation of laser therapy for GSM management. Competing Interests: Conflicts to interest: none to declare. (© 2024. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu